Skip to main content
OpenTrials

Clinical trial condition

Carcinoma, Bronchogenic

Explore clinical trials studying Carcinoma, Bronchogenic. Study availability and eligibility vary by location and protocol.

5,229 public trials 1,177 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma, Bronchogenic trial results

Active, Not Recruiting

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

NCT03052608

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +7 more
Locations
  • Florida Cancer Specialists Altamonte Springs, Florida, United States
  • Florida Cancer Specialists Brandon, Florida, United States
  • Florida Cancer Specialists Clearwater, Florida, United States
  • Florida Cancer Specialists Gainesville, Florida, United States
View all 166 locations
View Trial Details
Active, Not Recruiting

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

NCT03703297

Conditions
Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, +11 more
Locations
  • Research Site Tucson, Arizona, United States
  • Research Site Santa Rosa, California, United States
  • Research Site New Haven, Connecticut, United States
  • Research Site Fort Myers, Florida, United States
View all 183 locations
View Trial Details
Active, Not Recruiting

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

NCT06140836

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +7 more
Locations
  • Local Institution - 0221 Des Moines, Iowa, United States
  • Local Institution - 0075 Boston, Massachusetts, United States
  • Local Institution - 0201 Boston, Massachusetts, United States
  • Local Institution - 0210 Mineola, New York, United States
View all 122 locations
View Trial Details
Active, Not Recruiting

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

NCT05238883

Conditions
Adenocarcinoma, Adenoma, Bronchial Neoplasms, +57 more
Locations
  • Mayo Clinic Scottsdale, Arizona, United States
  • USC/Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Mayo Clinic Jacksonville, Florida, United States
  • Mayo Clinic Rochester, Minnesota, United States
View Trial Details
Active, Not Recruiting

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

NCT03319940

Conditions
Bites and Stings, Bronchial Neoplasms, Carcinoma, Bronchogenic, +11 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • Yale New Haven Hospital New Haven, Connecticut, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Winship Cancer Institute Atlanta, Georgia, United States
View all 39 locations
View Trial Details
Active, Not Recruiting

Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment

NCT05382052

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Hospital Universitario De A Coruna A Coruña, Spain
  • Hospital General Universitario de Alicante Alicante, Spain
  • Hospital Germans Trias I Pujol Badalona, Barcelona, Spain
  • Hospital Universitari Quiron Dexeus Barcelona, Spain
View all 20 locations
View Trial Details
Active, Not Recruiting

Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy

NCT05781308

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • CHU Amiens Amiens, France
  • CHU d'Angers Angers, France
  • CH Avignon Avignon, France
  • CH Côte Basque Bayonne, France
View all 44 locations
View Trial Details

Related conditions